AWM
TRVI icon

Avior Wealth Management’s Trevi Therapeutics TRVI Stock Holding History

Avior Wealth Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$20 – 3625
2024
Q1 		$20 Buy
+6
New +$13 ﹤0.01% 3687

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Avior Wealth Management's TRVI Position: Q2 2024 in Review

Avior Wealth Management sold out of Trevi Therapeutics (TRVI) in Q2 2024, closing a stake of 6 shares — an estimated $20 sold.

Avior Wealth Management first reported a position in TRVI in Q1 2024 and held it in 1 quarter. The position peaked at $20 in Q1 2024. 77 funds tracked by Wall St. Rank hold TRVI as of Q2 2024.

  • Avior Wealth Management reported no remaining Trevi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 6 Trevi Therapeutics shares in Q2 2024, an estimated $20.
  • Avior Wealth Management first reported a position in Trevi Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Trevi Therapeutics position peaked at $20 in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.